Innovation Pharmaceuticals Inc (IPIX)

[rmzport]

cabel Wednesday, 05/10/17 09:02:58 PM
Re: None 0
Post # of 235025

Repeat post:

I think we have 3 major points in our favor for the Prurisol Phase 2B trial.

1) we are upping the mg by 50% and 100% and already we saw that P was administered in a Phase 1 trial up to 850mg with no adverse side effects. We were also told that the drug is DOSE DEPENDANT so the more administered the more effective it should be.

2) We are attacking Moderate to Severe Psoriasis in the 2B rather than the Mild to Moderate in the 2A,... It is more of a challenge to get the Mild psoriasis to disappear than to reduce the Severe to Moderate or the Moderate to Mild. Of course we might see that we are the only drug on the market that will be able to treat the Mild effectively,... the Mild being the biggest market of all. Most mild patients do not even seek drug treatments as the side effects are usually worse that the Mild version of the disease.

3) We are using PASI standard in 2B instead of the point standard used in 2A. We were looking for a 2 point reduction of the point standard in 2A... which would have translated to a PASI90,.. whereas now if we get PASI75 of 50% we will skyrocket and surely be able to make a deal.